Cooperative Agreement UG3HL181184
Award Date 9/5/25
Completion Date 8/31/26
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
California, USA
Similar Awards
- This federal Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $318,167 to the University of Alabama at Birmingham (UAB) to conduct the Women's Aneurysm Research: Repair Immediately or Routine Surveillance (WARRIORS) Trial. This international, randomized controlled trial will compare early elective endovascular aortic repair (EVAR) to routine surveillance for women aged 50 and older...
- This federal Project Grant award of $686,685 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to study the genetic and epigenetic factors that influence the development of abdominal aortic aneurysms (AAA) related to tobacco use. The primary awardee, The Leland Stanford Junior University, will leverage its expertise in vascular biology and genetic research to develop an innovative mouse model of chronic tobacco-induced AAA. The...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,364,080 project grant to Vesteck, Inc. on September 15, 2025. The grant supports the development and feasibility testing of Vesteck's novel endovascular suturing device for augmenting endograft fixation during endovascular repair of abdominal aortic aneurysms (AAAs). The device aims to reduce reinterventions due to endograft migration or type 1A...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,998,124 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) for a Phase 2 clinical trial studying the use of elafin (tiprelestat) as a treatment for pulmonary arterial hypertension (PAH). The award supports a 3-arm, randomized, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of daily subcutaneous elafin...
- The University of Cincinnati, through its Sponsored Research Services Division, was awarded a $156,276 project grant by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on "Hematopoietic Cells and Chemokine Regulation in Abdominal Aortic Aneurysm Associated Thrombosis". The project, with a performance period from August 1, 2025 to June 30, 2027, aims to investigate the role of platelet activation and...
- This $722,299 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a research initiative to use deep learning techniques to study normal variation in aortic valve hemodynamics and its link to the development of aortic stenosis. The primary objectives are to: 1) Measure aortic valve parameters in 100,000 UK Biobank participants using deep learning models, validate the measurements at UCSF, and develop models to identify...
- This $740,338 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of Protease Activated Receptor 2 (PAR2) in the initiation and progression of abdominal aortic aneurysms (AAAs). The research aims to determine how PAR2 expression and activity in vascular smooth muscle cells may impact the structural integrity of the aortic wall and contribute to AAA...
- This Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Aneurisk, Inc. to develop and validate machine learning models for risk classification, growth projection, and wall stress prediction for abdominal aortic aneurysms (AAA). The project aims to create an artificial intelligence-based clinical decision support tool that enables clinicians to improve the treatment of patients with...
- This $713,382 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pennsylvania on the role of triglyceride-rich lipoproteins in the growth and progression of abdominal aortic aneurysms. The research aims to generate definitive causal evidence on how triglyceride-rich lipoproteins influence the development, growth, and rupture of these life-threatening aortic aneurysms, with the goal...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...